Codexis - CDXS Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CDXS shares.
View CDXS analyst ratings or view top-rated stocks.

4 equities research analysts have issued 12-month price objectives for Codexis' stock. Their CDXS share price forecasts range from $15.00 to $23.00. On average, they predict the company's share price to reach $19.83 in the next twelve months. This suggests a possible upside of 222.0% from the stock's current price.
View analysts price targets for CDXS or view top-rated stocks among Wall Street analysts.

Codexis' stock was trading at $4.66 at the beginning of 2023. Since then, CDXS stock has increased by 32.2% and is now trading at $6.16.
View the best growth stocks for 2023 here.

Codexis saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 5,070,000 shares, a decrease of 7.0% from the December 31st total of 5,450,000 shares. Based on an average daily volume of 824,300 shares, the short-interest ratio is currently 6.2 days. Approximately 8.0% of the shares of the company are sold short.
View Codexis' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our CDXS earnings forecast.

Codexis, Inc. (NASDAQ:CDXS) issued its earnings results on Thursday, November, 4th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.12. The biotechnology company earned $36.77 million during the quarter, compared to analysts' expectations of $28.52 million. Codexis had a negative trailing twelve-month return on equity of 19.59% and a negative net margin of 23.49%. The company's revenue for the quarter was up 100.0% on a year-over-year basis. During the same period in the prior year, the company earned ($0.10) EPS.

Codexis issued an update on its FY 2022 earnings guidance on Thursday, November, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $135.00 million-$141.00 million, compared to the consensus revenue estimate of $137.10 million.

25 employees have rated Codexis Chief Executive Officer John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS).

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Codexis' stock is owned by many different retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (9.45%), ARK Investment Management LLC (6.00%), Sumitomo Mitsui Trust Holdings Inc. (1.66%), Assenagon Asset Management S.A. (1.38%), Allspring Global Investments Holdings LLC (0.87%) and Essex Investment Management Co. LLC (0.49%). Insiders that own company stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, John J Nicols, Patrick Y Yang and Thomas R Baruch.
View institutional ownership trends.

Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CDXS stock can currently be purchased for approximately $6.16.

Codexis (NASDAQ:CDXS) has a market capitalization of $404.65 million and generates $104.75 million in revenue each year. The biotechnology company earns $-21,280,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis.

The company employs 261 workers across the globe.

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.codexis.com. The biotechnology company can be reached via phone at (650) 421-8100, via email at ir@codexis.com, or via fax at 650-421-8102.